Search the Community
Showing results for tags 'doctors'.
I found this article and thought it worth sharing. I think it provides another stream of hope for overall fight for proper cannabis laws globally............................................................................................................. "Evidence mounts as a growing number of papers published in scientific journals are establishing that cannabinoids have anti-tumor effects on the cellular level and in animals. Increasing numbers of people have been using Cannabis “oil” —plant extracts consisting of 50% or more THC and/or CBD— to treat conditions ranging from mild rashes to potentially fatal cancers. Reports of success are circulating among medical Cannabis users and on the internet. They gain plausibility from a parallel stream of papers published in scientific journals establishing that cannabinoids have anti-tumor effects on the cellular level and in animals. The anti-cancer properties of cannabinoids were a recurring theme at this year’s meeting of the International Cannabinoid Research Society, and also in a course for physicians presented Oct. 24, 2012, at the University of California San Francisco. One speaker, Jeffrey Hergenrather, MD, described a particularly dramatic case seen by a San Diego colleague: a 90% reduction in the size of an infant’s brain tumor achieved over the course of a year by parents applying hemp oil to the baby’s pacifier before naptime and bedtime. Aptly dubbed “MMJ13001A” on the UCSF website, the half-day course on cannabinoid medicine included talks by three researchers whose findings about cannabis and cancer have been under-reported, to put it mildly: Stephen Sidney, MD, director of research for Kaiser-Permanente in Northern California; UCLA pulmonologist Donald Tashkin, MD; and Donald Abrams, MD, Chief of Hematology-Oncology at San Francisco General Hospital. Some 60 doctors received continuing medical education credits for attending the half-day course at UCSF’s Laurel Heights auditorium, which was organized by the Canadian Consortium for the Investigation of Cannabinoids, with help from Abrams and the Society of Cannabis Clinicians, and reprised the next day in Santa Monica (MMJ13001B). A very interested auditor at the UCSF session, Michelle Aldrich, had used cannabis oil as a treatment for lung cancer. Donald Abrams, who consulted on Aldrich's case, says, “The fact that Michelle didn’t have cancer that could be located [after using the oil] is a bit unusual in someone who started treatment with an advanced stage. I don’t usually see that in my patients. Did the cannabis oil make a difference? We don’t know because we don’t have a controlled study.” Abrams has met with a UCSF neurooncologist “to discuss whether or not we should do a clinical trial adding oil to chemo for patients with glioblastoma [a brain tumor that is usually fast-moving and fatal]. Manuel Guzman’s studies have shown that cannabinoids have great potential in treating brain tumors.” Undoubtedly Dr. Mahmoud ElSohly, who grows marijuana for the National Institute on Drug Abuse, can produce a uniform, highly concentrated extract for research purposes. But whether or not NIDA will let Abrams have some is uncertain. Abrams has jumped through bureaucratic hoops before. He has obtained all the necessary approvals and funding to conduct clinical trials involving cannabis, and published his findings in peer-reviewed journals. Because chemotherapy has a measurable benefit, he says, “There’s no way we could get approval for a study that evaluates cannabis oil as a cure for brain tumors without giving patients temolozide [the standard treatment for glioma].” “A ‘cure’ in cancer means five years of disease-free survival,” Abrams reminds us. So what Abrams has in mind is “a study of the pharmacokinetic interaction between cannabis oil and temolozide.” Participants would be patients undergoing treatment for glioblastoma. Researchers would measure the level of temolozide in their blood before and after adding cannabis oil to their regimen. The primary objective would be to establish safety —to confirm that large cannabinoid infusions do not interfere with the body’s ability to process temolozide. Another objective would be to document examples of cannabis oil expediting or promoting tumor reduction. Such a ‘signal’ might justify a trial of cannabis oil on its own. Abrams does not want to promote false hope. “I do integrative oncology,” he says, “so I hear about ‘miracle cures’ all the time. I hear about about noni juice and graviola and many products. What’s disturbing is to hear people talking about cannabis oil as a ‘cure,’ because a cure in cancer means five years of disease-free survival and people have not been using cannabis oil for five years. “I think it does a disservice to the cannabis community to make claims that are not supportable. I may be seen as a nay-sayer but I’m not. I say ‘Let’s study it.’”
UK Doctors Given the Green Light To Prescribe Bedrocan Medicinal Cannabis 25 Andrew Turner MP On 13th November 2012, Andrew Turner, Tory MP for the Isle of Wight, received a written answer to a question he had submitted to the Secretary of State for Health. ”To ask the Secretary of State for Health whether Bedrocan and Bediol forms of cannabis are available(a) under prescription and ( on the NHS?” Bedrocan and Bediol are two of the four varieties of medicinal cannabis available from the Dutch governments official producer. See here for details. Norman Lamb MP, Health Minister Norman Lamb, LibDem MP for North Norfolk and minster of state at the Department of Health, replied saying: “Neither Bedrocan nor Bediol are licensed as medicines for use in the United Kingdom. Clinicians can prescribe any product, including any unlicensed product, subject to their primary care organisation agreeing funding, if they feel it is clinically appropriate for an individual patient after discussing the potential risks and taking into account the patient’s medical history. In these circumstances, the clinician is expected to retain clinical responsibility for the patient while prescribing the medicine.” CLEAR is now in correspondence with both the Department of Health and the Home Office seeking clarification. Source: Hansard Bedrocan® The THC-level of Bedrocan© is constant around 19 %. The CBD-level is lower as1%. This product is available as Cannabis Flos variety Bedrocan®. All varieties are guaranteed free of pesticides and heavy metals. It is also purged of any micro organisms. Bedrocan, Bedrobinol and Bediol are supplied in packages of 5 grams only. Distributor is Fagron Pharmaceuticals in Nieuwekerk aan de IJssel. Cannabis Flos variations Bedrocan is is a medical substance registered under Dutch law. copied and pasted from - http://www.clear-uk.org/uk-doctors-given-the-green-light-to-prescribe-bedrocan-medicinal-cannabis/ Peace Lams